NeuroPace (NPCE) says it remains on track to submit NAUTILUS data to the FDA for potential IGE indication expansion in the second half of 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NPCE Upcoming Earnings Report: What to Expect?
- NeuroPace ‘commends’ CMS for maintaining FY25 epilepsy reimbursement structure
- Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
- NeuroPace Appoints New CFO Amid Strategic Shift
- NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed